• Product NameLinifanib (ABT-869)
• Brief DescriptionInhibitors
• Purification99.97%
• Biological ActivityLinifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent Y cells (i.e. FLT3). Phase 3.
• Target Namec-Kit inhibitor; CSF-1R inhibitor; FLT inhibitor; VEGFR inhibitor
• CAS No. 796967-16-3
• Calculated MW 375.4
• Formulation C21H18FN5O
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC1=CC(NC(=O)NC2=CC=C(C=C2)C2=C3C(N)=NNC3=CC=C2)=C(F)C=C1
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:Kit; CSF-1R; FLT3; VEGFR1/FLT1; VEGFR2/KDR
  Boling pt:
  Melting pt:
  Solubility:DMSO: 75 mg/mL (199.78 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Albert DH, et al. Mol Y Ther, 2006, 5(4), 995-1006.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting